Cargando…

Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection

Because prolonged viral replication of SARS-CoV-2 is increasingly being recognized among immunocompromised patients, subacute or chronic COVID-19 pneumonia can cause persistent lung damage and may lead to viral escape phenomena. Highly efficacious antiviral therapies in immunosuppressed hosts with C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wada, Daiki, Nakamori, Yasushi, Maruyama, Shuhei, Shimazu, Haruka, Saito, Fukuki, Yoshiya, Kazuhisa, Kuwagata, Yasuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462070/ https://www.ncbi.nlm.nih.gov/pubmed/36085172 http://dx.doi.org/10.1186/s40164-022-00307-9

Ejemplares similares

Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study
por: Shimazu, Haruka, et al.
Publicado: (2023)

A descriptive study of abdominal complications in patients with mild COVID-19 presenting to the emergency department: a single-center experience in Japan during the omicron variant phase
por: Maruyama, Shuhei, et al.
Publicado: (2023)

Combined brain and thoracic trauma surgery in a hybrid emergency room system: a case report
por: Wada, Daiki, et al.
Publicado: (2021)

A paediatric case of severe tracheobronchial injury successfully treated surgically after early CT diagnosis and ECMO safely performed in the hybrid emergency room
por: Wada, Daiki, et al.
Publicado: (2019)

Hybrid emergency room: Installation, establishment, and innovation in the emergency department
por: Wada, Daiki, et al.
Publicado: (2023)

Peak value of serum KL-6 may be useful for predicting poor prognosis of severe COVID-19 patients
por: Maruyama, Shuhei, et al.
Publicado: (2022)

Idarucizumab for a traumatic head injury patient taking dabigatran
por: Maruyama, Shuhei, et al.
Publicado: (2018)

A case of blunt thoracic aortic injury requiring ECMO for acute malperfusion before TEVAR
por: Wada, Daiki, et al.
Publicado: (2017)

First installation of a dual-room IVR-CT system in the emergency room
por: Wada, Daiki, et al.
Publicado: (2018)

A novel technique of differential lung ventilation in the critical care setting
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Impact on survival of whole-body computed tomography before emergency bleeding control in patients with severe blunt trauma
por: Wada, Daiki, et al.
Publicado: (2013)

Neutralizing antiviral antibody responses
por: Zinkernagel, Rolf M., et al.
Publicado: (2001)

Orthobunyavirus spike architecture and recognition by neutralizing antibodies
por: Hellert, Jan, et al.
Publicado: (2019)

Antiviral neutralizing antibodies: from in vitro to in vivo activity
por: Burton, Dennis R.
Publicado: (2023)

Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals
por: Stelitano, Debora, et al.
Publicado: (2021)

Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD
por: Chen, Yaozong, et al.
Publicado: (2022)

Structures of Omicron spike complexes and implications for neutralizing antibody development
por: Guo, Hangtian, et al.
Publicado: (2022)

Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies
por: Zhang, Zhiqing, et al.
Publicado: (2016)

Assessment of risk factors related to healthcare-associated methicillin-resistant Staphylococcus aureus infection at patient admission to an intensive care unit in Japan
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Neutralizing antibodies targeting SARS-CoV-2 spike protein
por: Xiaojie, Shi, et al.
Publicado: (2021)

Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients
por: Giot, Matthieu, et al.
Publicado: (2021)

A spike protein S2 antibody efficiently neutralizes the Omicron variant
por: Hu, Jia, et al.
Publicado: (2022)

SARS-CoV-2 spike S2-specific neutralizing antibodies
por: Li, Chia-Jung, et al.
Publicado: (2023)

SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
por: Yang, Yang, et al.
Publicado: (2021)

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
por: Pelegrin, Mireia, et al.
Publicado: (2015)

Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies
por: Xiang, Qi, et al.
Publicado: (2022)

Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
por: Furukawa, Hiroshi, et al.
Publicado: (2022)

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
por: Terpos, Evangelos, et al.
Publicado: (2021)

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
por: Coleman, Christopher M., et al.
Publicado: (2014)

Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies
por: Schuler, Charles F., et al.
Publicado: (2021)

Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID‐19
por: Huang, Jiansheng, et al.
Publicado: (2020)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
por: Alenquer, Marta, et al.
Publicado: (2021)

501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations
por: Ngo, Son Tung
Publicado: (2022)

Detection of SARS-CoV-2 Nucleocapsid, Spike, and Neutralizing Antibodies in Vaccinated Japanese
por: Midorikawa, Rie, et al.
Publicado: (2022)

Co-display of diverse spike proteins on nanoparticles broadens sarbecovirus neutralizing antibody responses
por: Brinkkemper, Mitch, et al.
Publicado: (2022)

Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
por: Miyashita, Naoyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kf9vo4lt9cmt40110uij9hci78